What is claimed is:

A method of administering a compound of the formula

$$\begin{array}{c|c} & H & H & O & H & CO_2R \\ \hline HO & OH & A & OH & A & A & A \\ \hline \end{array}$$

wherein X and Y are the same or different halo group; R is H or lower alkyl; and pharmaceutically acceptable salts thereof; together with a chemotherapeutic agent.

- A method according to Claim 1 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin; cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.
- A method according to Claim 1 wherein the compound is selected from the group consisting of:

4. A method according to Claim 3 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.

(5.)

A method of treating or preventing a neoplasia disease comprising administering to a mammal in need of treatment for a neoplasia disease a therapeutically effective amount of a compound of the formula:

wherein X and Y are the same or different halo group; R is H or lower alkyl; or a pharmaceutically acceptable salt thereof; together with a chemotherapeutic agent.

- 6. A method according to Claim 5 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.
- 7. A method according to Claim 5 wherein the compound is selected from the group consisting of

H N CO<sub>2</sub>R OH HO. Br' CO<sub>2</sub>R Ю HO ÒΗ Br<sub>1</sub> H CO<sub>2</sub>R OH N H HO - OH H N CO₂R OH HO' Br H N N H ОН HO

· 5

H N CO<sub>2</sub>R 'N' H OH HO<sup>2</sup> H N CO<sub>2</sub>R HO NH  $CO_2R$ OH; and HO ÓН NH  $CO_2R$ OH. HO ÓН

- 8. A method according to Claim 7 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.
  - 9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1, a chemotherapeutic agent and a pharmaceutically acceptable carrier.

- 10. A method according to Claim 5 wherein the neoplasia disease is tumor metastasis.
- 11. A method according to Claim 5 wherein the neoplasia disease treated is solid tumor growth.
- 12. A method according to Claim 5 wherein the condition treated is angiogenesis.
- 13. A method according to Claim 5 wherein the neoplasia disease is humoral hypercalcemia of malignancy.

Uq

010

0011

(1/2